Tandem Diabetes Care (NSDQ:TNDM) today posted third quarter earnings and lifted its sales guidance for the year, beating Wall Street expectations for sales but falling behind on losses-per-share.
The San Diego-based company posted losses of $34.2 million, or 62¢ per share, on sales of $46.3 million for the three months ended September 30, seeing losses grow 113.6% while sales grew 71.3% compared with the same period during the previous year.
Read the whole story on our sister site, Drug Delivery Business News
The post Tandem Diabetes Q3 sales top The Street appeared first on MassDevice.
from MassDevice https://ift.tt/2Oh1mDz
Cap comentari:
Publica un comentari a l'entrada